Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Nine Months ended December 31, 2003
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs.45.55 = U.S.$1.00
Business Overview: DRL operates in Formulations, Active Pharmaceutical Ingredients (API) and Intermediates, Generics, Diagnostics/Critical Care/Biotechnology, and Drug Discovery segments. The company is headquartered in Hyderabad, India.
Key Financial Metrics
Revenue (Nine Months Ended Dec 31, 2003): Rs.15,326.4 million (U.S.$336.5 million)
Net Income (Nine Months Ended Dec 31, 2003): Rs.2,312.0 million (U.S.$50.8 million)
Gross Profit (Nine Months Ended Dec 31, 2003): Rs.8,246.8 million (Gross Margin: 53.8%)
Operating Income (Nine Months Ended Dec 31, 2003): Rs.2,379.7 million
Cash Flow from Operations (Nine Months Ended Dec 31, 2003): Rs.2,881.5 million (U.S.$63.3 million)
Cash and Cash Equivalents (As of Dec 31, 2003): Rs.5,781.0 million (U.S.$126.9 million)
Total Debt (As of Dec 31, 2003): Rs.186.1 million (Long-term) + Rs.154.8 million (Current portion) = Rs.340.9 million total principal outstanding.
Stockholders' Equity (As of Dec 31, 2003): Rs.20,821.1 million (U.S.$457.1 million)
Material Changes vs. Prior Comparable Period
- Revenue Growth: Revenue increased 18.2% for the quarter and 11.0% for the nine months ended Dec 31, 2003, compared to the prior year periods. Growth was driven by the API and Formulations segments.
- Profitability Decline: Despite revenue growth, Net Income decreased 10.5% for the quarter and 16.9% for the nine months ended Dec 31, 2003. Operating income decreased 3.5% for the quarter.
- Margin Compression: Gross margin decreased to 52.0% for the quarter (from 54.4% prior year) and 53.8% for the nine months (from 54.5% prior year). This was primarily due to lower margins in the Generics segment and a shift in sales mix in the API segment.
- Expense Increases: R&D expenses surged 59.1% for the quarter due to bio-studies and new projects. SG&A expenses increased 18.2% for the quarter due to higher employee costs, marketing, and legal fees.
- Foreign Exchange: The company recorded a foreign exchange gain of Rs.61.8 million for the quarter, compared to a loss of Rs.36.3 million in the prior year, largely offsetting other operational pressures.
- Cash Flow: Net cash provided by operating activities decreased 17.2% for the nine months ended Dec 31, 2003, primarily due to lower net income and a significant increase in accounts receivable (Rs.578.2 million).
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
- API Segment: Focused on regulated markets (U.S. and Europe) with a pipeline of Drug Master Files (DMFs). Launched Ramipril in Europe.
- Formulations: Expecting growth in line with the Indian industry average (approx. 5.1%). Expanding presence in CIS markets, China, and Mexico.
- Generics: Growth in the U.S. driven by Fluoxetine. Facing severe competition in the U.K. for Omeprazole. Expanding ANDA pipeline.
- Specialty: Received final FDA approval for AmVaz (amlodipine maleate) in October 2003. Pending appeal regarding a patent infringement suit filed by Pfizer.
Risks and Contingencies:
- Price Control Litigation: Ongoing litigation regarding the pricing of Norfloxacin. If unsuccessful, the company may be required to refund excess sales proceeds estimated at Rs.179.8 million as of Dec 31, 2003.
- Regulatory Demands: Received demand notices from the National Pharmaceutical Pricing Authority (NPPA) regarding Cloxacillin and Ciprofloxacin sales (totaling approx. Rs.12.3 million plus interest). The company has reserved against these expenses and deposited 50% of the principal amount.
- Environmental Litigation: Named in a writ regarding pollution in Patancheru/Bollarum areas. Company considers further liability remote but has paid Rs.2.0 million in compensation.
- Guarantees: Holds a corporate guarantee of Rs.122.5 million for an affiliate (Pathnet). No liability accrued as payment is not considered probable.
Unusual Items:
- Acquisition of Minority Interest: Acquired remaining 10.2% of Reddy US Therapeutic Inc. (RUSTI) for Rs.90.4 million goodwill.
- Stock Compensation: Adopted SFAS 123 retroactively, recording Rs.76.3 million in stock-based compensation expense for the nine months ended Dec 31, 2003.
- Investment Activity: Significant cash outflow for investments (Rs.2,058.4 million), including Rs.1,500 million in non-convertible debentures from Citicorp Finance India Limited.
Investor Verification Checklist
- Verify the status and potential financial impact of the Norfloxacin price control litigation (potential refund liability of ~Rs.180 million).
- Monitor the resolution of the NPPA demand notices regarding Cloxacillin and Ciprofloxacin and the outcome of the interest levy challenge.
- Assess the impact of the Pfizer patent infringement appeal regarding the amlodipine maleate product (AmVaz) on future specialty revenue.
- Review the sustainability of the 59.1% increase in R&D expenses and its correlation with future product launches.
- Confirm the collectibility of the increased accounts receivable balance (up Rs.578 million), particularly regarding the major customer Par Pharmaceuticals (16.4% of total receivables).
- Validate the performance of the new European API launches (Ramipril) and the competitive landscape for Generics in the U.K. and U.S.